Synonym
Pramiracetam Sulfate; Pramiracetam; CI-879; CI 879; CI879; CNS-1879; CNS1879; CNS 1879; Pramistar
IUPAC/Chemical Name
N-(2-(diisopropylamino)ethyl)-2-(2-oxopyrrolidin-1-yl)acetamide sulfate
InChi Key
ACSROKXFXFNERX-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H27N3O2.H2O4S/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19;1-5(2,3)4/h11-12H,5-10H2,1-4H3,(H,15,18);(H2,1,2,3,4)
SMILES Code
O=C(NCCN(C(C)C)C(C)C)CN1C(CCC1)=O.O=S(O)(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#
68497-62-1(Pramiracetam)
72869-16-0(Pramiracetam Sulfate)
Preparing Stock Solutions
The following data is based on the
product
molecular weight
367.46
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fang Z, Liu X, Xiao Y, Jiang W. [Pharmacokinetics of pramiracetam in animals]. Hua Xi Yi Ke Da Xue Xue Bao. 1999 Dec;30(4):411-3. Chinese. PubMed PMID: 11387954.
2: Corasaniti MT, Paoletti AM, Palma E, Granato T, Navarra M, Nisticò G. Systemic administration of pramiracetam increases nitric oxide synthase activity in the cerebral cortex of the rat. Funct Neurol. 1995 May-Jun;10(3):151-5. PubMed PMID: 8557218.
3: Murray CL, Fibiger HC. The effect of pramiracetam (CI-879) on the acquisition of a radial arm maze task. Psychopharmacology (Berl). 1986;89(3):378-81. PubMed PMID: 3088666.
4: Maresová D, Mares P. The action of pramiracetam on consequences of hypobaric hypoxia is only moderate. Physiol Res. 1996;45(3):245-8. PubMed PMID: 9200217.
5: Auteri A, Blardi P, Celasco G, Segre G, Urso R. Pharmacokinetics of pramiracetam in healthy volunteers after oral administration. Int J Clin Pharmacol Res. 1992;12(3):129-32. PubMed PMID: 1473879.
6: McLean A Jr, Cardenas DD, Burgess D, Gamzu E. Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia. Brain Inj. 1991 Oct-Dec;5(4):375-80. PubMed PMID: 1786500.
7: Brust P. Reversal of scopolamine-induced alterations of choline transport across the blood-brain barrier by the nootropics piracetam and pramiracetam. Arzneimittelforschung. 1989 Oct;39(10):1220-2. PubMed PMID: 2610714.
8: Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology. 1991 Apr;41(4):570-4. PubMed PMID: 2011259.
9: Chang T, Young RM, Goulet JR, Yakatan GJ. Pharmacokinetics of oral pramiracetam in normal volunteers. J Clin Pharmacol. 1985 May-Jun;25(4):291-5. PubMed PMID: 4008675.
10: Butler DE, Nordin IC, L'Italien YJ, Zweisler L, Poschel PH, Marriott JG. Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam. J Med Chem. 1984 May;27(5):684-91. PubMed PMID: 6716406.
